The Cladribine market is gaining traction globally, driven by its increasing use in treating multiple sclerosis (MS) and certain cancers such as hairy cell leukemia. Cladribine, a synthetic purine nucleoside analogue, disrupts DNA synthesis in rapidly dividing cells, making it an effective treatment for these proliferative conditions. Originally approved for hematologic cancers, Cladribine has now been repurposed as an oral therapy for relapsing forms of MS, offering patients a more...